SG Americas Securities LLC Lowers Position in TransMedics Group, Inc. (NASDAQ:TMDX)

SG Americas Securities LLC lessened its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 60.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,359 shares of the company's stock after selling 12,830 shares during the quarter. SG Americas Securities LLC's holdings in TransMedics Group were worth $1,312,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of TMDX. Wasatch Advisors LP acquired a new position in TransMedics Group during the first quarter worth $32,162,000. Vaughan Nelson Investment Management L.P. acquired a new position in shares of TransMedics Group during the 2nd quarter valued at about $39,862,000. Driehaus Capital Management LLC grew its holdings in shares of TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company's stock valued at $223,832,000 after purchasing an additional 202,867 shares during the period. First Light Asset Management LLC grew its holdings in shares of TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company's stock valued at $59,538,000 after purchasing an additional 136,217 shares during the period. Finally, Hood River Capital Management LLC acquired a new stake in TransMedics Group during the second quarter worth about $18,854,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the transaction, the insider now directly owns 20,843 shares of the company's stock, valued at $3,089,766.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company's stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company's stock, valued at approximately $8,948,714.31. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now directly owns 20,843 shares of the company's stock, valued at $3,089,766.32. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,205 shares of company stock worth $10,089,374 over the last 90 days. 7.00% of the stock is owned by insiders.

TransMedics Group Stock Down 0.9 %

NASDAQ:TMDX traded down $1.28 during mid-day trading on Thursday, hitting $135.90. The stock had a trading volume of 578,945 shares, compared to its average volume of 832,938. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $177.37. The stock has a 50-day simple moving average of $155.81 and a two-hundred day simple moving average of $135.46. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The company has a market capitalization of $4.48 billion, a PE ratio of -398.59 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analysts' expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company's revenue for the quarter was up 117.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.03) EPS. On average, equities research analysts anticipate that TransMedics Group, Inc. will post 1.22 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TMDX. Needham & Company LLC started coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They issued a "buy" rating and a $208.00 price target for the company. Stephens raised their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an "overweight" rating in a research note on Friday, August 2nd. Robert W. Baird initiated coverage on TransMedics Group in a research note on Tuesday, September 24th. They issued an "outperform" rating and a $200.00 price target on the stock. Canaccord Genuity Group increased their price target on TransMedics Group from $117.00 to $169.00 and gave the stock a "buy" rating in a report on Thursday, August 1st. Finally, Piper Sandler restated an "overweight" rating and issued a $180.00 price objective on shares of TransMedics Group in a report on Monday. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, TransMedics Group has a consensus rating of "Buy" and a consensus price target of $174.30.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.